🚀 VC round data is live in beta, check it out!
CytomX Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for CytomX Therapeutics and similar public comparables like Gen İlaç, Phathom Pharmaceuticals, Keqian Biology, CureVac and more.
CytomX Therapeutics Overview
About CytomX Therapeutics
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
Founded
2010
HQ
Employees
121
Website
Sectors
Financials (LTM)
EV
$907M
CytomX Therapeutics Financials
CytomX Therapeutics reported last 12-month revenue of $60M and negative EBITDA of ($56M).
In the same LTM period, CytomX Therapeutics generated $60M in gross profit, ($56M) in EBITDA losses, and had net loss of ($41M).
Revenue (LTM)
CytomX Therapeutics P&L
In the most recent fiscal year, CytomX Therapeutics reported revenue of $76M and EBITDA of ($21M).
CytomX Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $60M | XXX | $76M | XXX | XXX | XXX |
| Gross Profit | $60M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($56M) | XXX | ($21M) | XXX | XXX | XXX |
| EBITDA Margin | (93%) | XXX | (28%) | XXX | XXX | XXX |
| EBIT Margin | (73%) | XXX | (29%) | XXX | XXX | XXX |
| Net Profit | ($41M) | XXX | ($17M) | XXX | XXX | XXX |
| Net Margin | (69%) | XXX | (23%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
CytomX Therapeutics Stock Performance
CytomX Therapeutics has current market cap of $1B, and enterprise value of $907M.
Market Cap Evolution
CytomX Therapeutics' stock price is $4.81.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $907M | $1B | -1.6% | XXX | XXX | XXX | $-0.08 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCytomX Therapeutics Valuation Multiples
CytomX Therapeutics trades at 15.1x EV/Revenue multiple, and (16.2x) EV/EBITDA.
EV / Revenue (LTM)
CytomX Therapeutics Financial Valuation Multiples
As of April 19, 2026, CytomX Therapeutics has market cap of $1B and EV of $907M.
Equity research analysts estimate CytomX Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CytomX Therapeutics has a P/E ratio of (25.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $907M | XXX | $907M | XXX | XXX | XXX |
| EV/Revenue | 15.1x | XXX | 11.9x | XXX | XXX | XXX |
| EV/EBITDA | (16.2x) | XXX | (43.2x) | XXX | XXX | XXX |
| EV/EBIT | (20.6x) | XXX | (40.6x) | XXX | XXX | XXX |
| EV/Gross Profit | 15.1x | XXX | — | XXX | XXX | XXX |
| P/E | (25.2x) | XXX | (59.9x) | XXX | XXX | XXX |
| EV/FCF | (10.4x) | XXX | (12.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified CytomX Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
CytomX Therapeutics Margins & Growth Rates
CytomX Therapeutics' revenue in the last 12 month declined by (65%).
CytomX Therapeutics' revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.8M for the same period.
CytomX Therapeutics' rule of 40 is (686%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CytomX Therapeutics' rule of X is (793%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
CytomX Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (65%) | XXX | (71%) | XXX | XXX | XXX |
| EBITDA Margin | (93%) | XXX | (28%) | XXX | XXX | XXX |
| EBITDA Growth | 153% | XXX | 549% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (686%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (793%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.6M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 51% | XXX | 39% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 121% | XXX | 90% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 129% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
CytomX Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| CytomX Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Gen İlaç | XXX | XXX | XXX | XXX | XXX | XXX |
| Phathom Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Keqian Biology | XXX | XXX | XXX | XXX | XXX | XXX |
| CureVac | XXX | XXX | XXX | XXX | XXX | XXX |
| Annexon | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CytomX Therapeutics M&A Activity
CytomX Therapeutics acquired XXX companies to date.
Last acquisition by CytomX Therapeutics was on XXXXXXXX, XXXXX. CytomX Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by CytomX Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCytomX Therapeutics Investment Activity
CytomX Therapeutics invested in XXX companies to date.
CytomX Therapeutics made its latest investment on XXXXXXXX, XXXXX. CytomX Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by CytomX Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout CytomX Therapeutics
| When was CytomX Therapeutics founded? | CytomX Therapeutics was founded in 2010. |
| Where is CytomX Therapeutics headquartered? | CytomX Therapeutics is headquartered in United States. |
| How many employees does CytomX Therapeutics have? | As of today, CytomX Therapeutics has over 121 employees. |
| Who is the CEO of CytomX Therapeutics? | CytomX Therapeutics' CEO is Sean A. McCarthy. |
| Is CytomX Therapeutics publicly listed? | Yes, CytomX Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of CytomX Therapeutics? | CytomX Therapeutics trades under CTMX ticker. |
| When did CytomX Therapeutics go public? | CytomX Therapeutics went public in 2015. |
| Who are competitors of CytomX Therapeutics? | CytomX Therapeutics main competitors are Gen İlaç, Phathom Pharmaceuticals, Keqian Biology, CureVac. |
| What is the current market cap of CytomX Therapeutics? | CytomX Therapeutics' current market cap is $1B. |
| What is the current revenue of CytomX Therapeutics? | CytomX Therapeutics' last 12 months revenue is $60M. |
| What is the current revenue growth of CytomX Therapeutics? | CytomX Therapeutics revenue growth (NTM/LTM) is (65%). |
| What is the current EV/Revenue multiple of CytomX Therapeutics? | Current revenue multiple of CytomX Therapeutics is 15.1x. |
| Is CytomX Therapeutics profitable? | No, CytomX Therapeutics is not profitable. |
| What is the current EBITDA of CytomX Therapeutics? | CytomX Therapeutics has negative EBITDA and is not profitable. |
| What is CytomX Therapeutics' EBITDA margin? | CytomX Therapeutics' last 12 months EBITDA margin is (93%). |
| What is the current EV/EBITDA multiple of CytomX Therapeutics? | Current EBITDA multiple of CytomX Therapeutics is (16.2x). |
| What is the current FCF of CytomX Therapeutics? | CytomX Therapeutics' last 12 months FCF is ($87M). |
| What is CytomX Therapeutics' FCF margin? | CytomX Therapeutics' last 12 months FCF margin is (144%). |
| What is the current EV/FCF multiple of CytomX Therapeutics? | Current FCF multiple of CytomX Therapeutics is (10.4x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.